Drugs / LUCAR-20SP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06313957 | Mar 2024 → Sep 2026 overdue | B-cell non-Hodgkin lymphoma | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUCAR-20SP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06313957 ↗ |
| Route | Other | “Patients who meet the eligibility criteria will receive LUCAR-20SP infusion” NCT06313957 ↗ |